Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide + SGLT2i in Type 2 Diabetes (DIPPER Pilot)
NCT07902726Phase 2Not yet recruiting
- Sponsor
- University Health Network
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acetazolamide in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), sponsored by University Health Network. Primary endpoint: Iohexol Measured Glomerular Filtration Rate at 16 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
acetazolamide
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07902726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902726.